1887

Abstract

The and genes from feline leukaemia virus were expressed in a thymidine kinase-negative feline herpesvirus and a baculovirus. Cats were vaccinated with various combinations of these recombinant viruses and 100% protection against feline leukaemia virus challenge was achieved using an immunization schedule which utilized both env and gag products delivered at both a mucosal and systemic site.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-73-7-1811
1992-07-01
2021-10-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/73/7/JV0730071811.html?itemId=/content/journal/jgv/10.1099/0022-1317-73-7-1811&mimeType=html&fmt=ahah

References

  1. Akerblom L., Stromstedt S., Hoglund S., Osterhaus A., Morein B. 1989; Formation and characterization of FeLV ISCOMs. Vaccine 7:142–146
    [Google Scholar]
  2. Cole G. E., Stacy-Phipps S., Nunberg J. H. 1990; Recombinant feline herpesvirus expressing feline leukemia virus envelope and gag proteins. Journal of Virology 64:4930–4938
    [Google Scholar]
  3. De Noronha F., Grant C. K., Lutz H., Keyes A., Rouston W. 1983; Circulating levels of feline leukemia and sarcoma viruses and fibrosarcoma regression in persistently viremic cats. Cancer Research 43:1663–1668
    [Google Scholar]
  4. Donahue P. R., Hoen R. A., Belts G. A., Riedel N., Hirsch V. M., Overbaug J., Mullins J. 1988; Strong sequence conservation among horizontally transmissible minimally pathogenic feline leukemia viruses. Journal of Virology 62:722–731
    [Google Scholar]
  5. Flyer D. C., Burakoff S. J., Faller D. V. 1983; Cytotoxic T lymphocyte recognition of transfected cells expressing a cloned retroviral gene. Nature London 305:815–818
    [Google Scholar]
  6. Francis D. P., Essex M., Hardy W. D. 1977; Excretion of feline leukaemia virus by naturally infected pet cats. Nature, London 269:252–254
    [Google Scholar]
  7. Gaskell R. M., Povey R. C. 1979; The dose reponse of cats to experimental infection with feline rhinotracheitis virus. Journal of Comparative Pathology 89:179–191
    [Google Scholar]
  8. Germain R. N. 1986; The ins and outs of antigen processing and presentation. Nature, London 322:687–689
    [Google Scholar]
  9. Grant C. K., de Noronha F., Tusch C., Michalek M. T., McLane M. F. 1980a; Protection of cats against progressive firbrosarcoma and persistent leukemia virus infection by vaccination with feline leukemia cells. Journal of the National Cancer Institute 65:1285–1292
    [Google Scholar]
  10. Grant C. K., Essex M., Gardner M. B., Hardy W. D. 1980b; Natural feline leukemia virus infection and the immune response of cats of different ages. Cancer Research 40:832–398
    [Google Scholar]
  11. Grant C. K., Ernisee B. J., Jarrett O., Jones F. R. 1983; Feline leukemia virus envelope gp70 of subgroups B and C defined by monoclonal antibodies with cytotoxic and neutralizing functions. Journal of Immunology 131:3042–3048
    [Google Scholar]
  12. Halstead S. B. 1988; Pathogenesis of dengue: challenges to molecular biology. Science 239:476–481
    [Google Scholar]
  13. Hardy W. D. 1980; The virology, immunology and epidemiology of the feline leukemia virus. In Feline Leukemia Virus pp 33–78 Edited by Hardy W. D., Essex M., McClelland A. J. Amsterdam: Elsevier;
    [Google Scholar]
  14. Hardy W. D., Old L. J., Hess P. W., Essex M., Cotter S. 1973; Horizontal transmission of feline leukaemia virus. Nature, London 244:266–267
    [Google Scholar]
  15. Holt C. A., Osorio K., Lilly F. 1986; Friend virus-specific cytotoxic T lymphocytes recognize both gag and env gene-encoded specificities. Journal of Experimental Medicine 164:211–226
    [Google Scholar]
  16. Jarrett W. F. H., Crawford E. M., Martin W. B., Davie F. 1964; A virus-like particle associated with leukaemial lymphosarcoma. Nature, London 2JS/2567–569
    [Google Scholar]
  17. Jarrett W., Jarrett O., Mackey L., Laird H., Hood C., Hay D. 1975; Vaccination against feline leukemia virus using a cell membrane antigen system. International Journal of Cancer 16:134–140
    [Google Scholar]
  18. Jeggo M. H., Wardley R. C. 1982; Generation of cross-reactive cytotoxic T lymphocytes following immunization of mice with various bluetongue virus types. Immunology 45:629–636
    [Google Scholar]
  19. Kimman T. G., Westenbrink F., Straw P. J. 1989; Priming for lead and systemic antibody memory responses to bovine respiratory syncytial virus: effect of amount of virus replication, route of administration and material antibodies. Veterinary Immunology and Immunopathology 22:145–160
    [Google Scholar]
  20. Kit M., Kit S., Little S. P., Di Marchi R. D., Gale C. 1991; Bovine herpesvirus-1 (infectious bovine rhinotracheitis virus)-based viral vector which expresses foot-and-mouth disease epitopes. Vaccine 9:564–572
    [Google Scholar]
  21. Lewis M. G., Mathes L. E., Olsen R. G. 1981; Protection against feline leukemia by vaccination with a subunit vaccine. Infections and Immunity 34:888–893
    [Google Scholar]
  22. Lutz H., Pedersen N., Higgins J., Hubscher U., Troy F. A., Theilen G. H. 1980; Humoral immune reactivity to feline leukemia virus and associate antigens in cats naturally infected with feline leukemia virus. Cancer Research 40:3642–3651
    [Google Scholar]
  23. Lycke N., Hellstrom U., Holmgren J. 1987; Circulating cholera antitoxin memory cells in the blood one year after oral cholera vaccination in humans. Scandinavian Journal of Immunology 26:207–211
    [Google Scholar]
  24. McCarty J. M., Grant C. K. 1983; Feline cytotoxic immune mechanisms against virus-associated leukemia and fibrosarcoma. Cellular Immunology 81:157–168
    [Google Scholar]
  25. Manjunath R., Graziano R. F., Green W. R. 1986; The specificity of H-2-restricted cytotoxic T lymphocytes directed to AKR/Gross leukemia virus-induced tumors. III. Coordinate alterations in viral gp70 antigen expression and restoration of CTL-susceptibility to insusceptible variant tumors. Journal of Immunology 136:2271–2279
    [Google Scholar]
  26. Manzanec M. B., Nedrud J. G., Lamm M. E. 1987; Immunoglobulin A monoclonal antibodies protect against Sendai virus. Journal of Virology 61:2624–2626
    [Google Scholar]
  27. Martin S., Rouse B. T. 1990; The control of human herpesvirus infections by cytotoxic T lymphocytes (CTL): a comparison to AIDS virus specific CTL. In Herpesviruses, the Immune System and AIDS pp 73–98 Edited by Aurelian L. Norwell: Kluwer Academic;
    [Google Scholar]
  28. Mathes L. E., Olsen R. G., Hebebrand L. C., Hoover E. A., Schaller J. P. 1978; Abrogation of lymphocyte blastogenesis by a feline leukaemia virus protein. Nature, London 274:687–689
    [Google Scholar]
  29. Mathes L. E., Olsen R. G., Hebebrand L. C., Hoover E. A., Schaller J. P., Adams P. W., Nichols W. S. 1979; Immunosuppressive properties of a virion polypeptide, a 15, 000 dalton protein from feline leukemia virus. Cancer Research 39:950–955
    [Google Scholar]
  30. Nick S., Klaws J., Friebel K., Birr C., Hunsmann G., Bayer H. 1990; Virus neutralizing and enhancing epitopes characterized by synthetic oligopeptides derived from the feline leukaemia virus glycoprotein sequence. Journal of General Virology 71:77–83
    [Google Scholar]
  31. Nunberg J. H., Rodgers G., Gilbert J. H., Snead R. M. 1984; Methods to map antigenic determinants recognized by monoclonal antibodies: localization of a determinant of virus neutralization on the feline leukemia virus envelope gp70. Proceedings of the National Academy of Sciences, U.S.A. 81:3675–3679
    [Google Scholar]
  32. Nunberg J. H., Wright D. K., Cole G. E., Petrovskis E. A., Post L. E., Compton T., Gilbert J. H. 1989; Identification of the thymidine kinase gene of feline herpesvirus: use of degenerate oligonucleotides in the polymerase chain reaction to isolate herpesvirus gene homologs. Virology 63:3240–3249
    [Google Scholar]
  33. Olsen R. G., Hoover E. A., Schaller J. P., Mathes L. E., Wolff L. H. 1977; Abrogation of resistance to feline coronavirus disease by immunization with killed feline leukemia virus. Cancer Research 37:2082–2085
    [Google Scholar]
  34. Osterhaus A., Weijer K., UytdeHaag F., Knell P., Jarrett O., Sundquist B., Morein B. 1985; Induction of protective immune response in cats by vaccination with feline leukemia virus ISCOM. Journal of Immunology 135:591–596
    [Google Scholar]
  35. Osterhaus A., Weijer K., UytdeHaag F., Knell P., Jarrett O., Akerblom L., Morein B. 1989; Serological responses in cats vaccinated with FeLV ISCOM and an inactivated FeLV vaccine. Vaccine 7:137–141
    [Google Scholar]
  36. Pedersen N. C., Johnson L., Bird C., Theilen G. H. 1986; Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective. Veterinary Immunology and Immunopathology 11:123–148
    [Google Scholar]
  37. Pierce N. F., Cray W. C. 1981; Cellular dissemination of priming for a mucosal immune response to cholera toxin in rats. Journal of Immunology 127:2461–2464
    [Google Scholar]
  38. Pierce N. F., Cray W. C. 1982; Determinants of localization, magnitude, and duration of a specific mucosal IgA plasma cell response in enterically immunized rats. Journal of Immunology 128:1311–1315
    [Google Scholar]
  39. Rojko J. L., Hoover E. A., Mathes L. E., Olsen R. G., Schaller J. P. 1979; Pathogenesis of experimental feline leukemia virus infection. Journal of the National Cancer Institute 63:759–768
    [Google Scholar]
  40. Rosenthal K. L., Zinkernagel R. N. 1980; Cross-reactive cytotoxic T cells to serologically distinct vesicular stomatitis virus. Journal of Immunology 144:2301–2310
    [Google Scholar]
  41. Russell P. H., Jarrett O. 1978; The specificity of neutralizing antibodies to feline leukemia viruses. International Journal of Cancer 21:768–773
    [Google Scholar]
  42. Salerno D. A., Lehman F. D., Casson U. M., Hilleman M. R. 1978; Feline leukemia virus envelope glycoprotein vaccine: preparation and evaluation of immunizing potency in guinea pig and cat. Journal of the National Cancer Institute 61:1487–1491
    [Google Scholar]
  43. Sarma P., Log T. 1973; Subgroup classification of feline leukemia and sarcoma viruses by viral interference and neutralisation tests. Virology 54:160–169
    [Google Scholar]
  44. Schaller J. P., Hoover E. A., Olsen R. G. 1977; Active and passive immunization of cats with inactivated feline oncornsaviruses. Journal of the National Cancer Institute 59:1441–1450
    [Google Scholar]
  45. Takeda A., Tuazon C. U., Ennis F. A. 1988; Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 242:580–583
    [Google Scholar]
  46. Theilen G. H., Kawakami T. G., Rush J. D., Munn R. J. 1969; Replication of cat leukemia virus in cell suspension cultures. Nature, London 222:589–590
    [Google Scholar]
  47. Thomsen D. R., Meyer A. L., Post L. E. 1992; Expression of feline leukaemia virus gp85 and gag proteins and assembly into virus-like particles using the baculovirus expression vector system. Journal of General Virology 73:1819–1824
    [Google Scholar]
  48. Van Der Hoorn F. A., Lahaye T., Muller V., Ogle M. A., Engers H. D. 1985; Characterization of gp85gag as an antigen recognized by Moloney leukemia virus-specific cytolytic T cell clones that function in vivo. Journal of Experimental Medicine 162:128–144
    [Google Scholar]
  49. Van Zijl M., Wensvoort G., De Kluyver E., Hulst M., Van Der Gulden H., Gielkens A., Berns A., Moormann R. 1991; Live attenuated pseudorabies virus expressing envelope glycoprotein E1 of hog cholera vius protects swine against both pseudorabies and hog cholera. Journal of Virology 65:2761–2765
    [Google Scholar]
  50. Zweerink H. J., Courtneidge S. A., Skehel J. J., Crumpton M. J., Askonas B. A. 1977; Cytotoxic T cells kill influenza virus-infected cells but do not distinguish between serologically distinct A viruses. Nature, London 267:354–361
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-73-7-1811
Loading
/content/journal/jgv/10.1099/0022-1317-73-7-1811
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error